Evidence
EMBO Rep. 2024 Feb 8. doi: 10.1038/s44319-024-00071-3. Online ahead of print.
ABSTRACT
Non-alcoholic fatty liver disease is a chronic liver abnormality that exhibits high variability and can lead to liver cancer in advanced stages. Hepatic ablation of SIRT6 results in fatty liver disease, yet the potential mechanism of SIRT6 deficiency, particularly in relation to downstream mediators for NAFLD, remains elusive. Here we identify Serpina12 as a key gene regulated by Sirt6 that plays a crucial function in energy homeostasis. Specifically, Sirt6 suppresses Serpina12 expression through histone deacetylation at its promoter region, after which the transcription factor, Cebpα, binds to and regulates its expression. Sirt6 deficiency results in an increased expression of Serpina12 in hepatocytes, which enhances insulin signaling and promotes lipid accumulation. Importantly, CRISPR-Cas9 mediated Serpina12 knockout in the liver ameliorated fatty liver disease caused by Sirt6 ablation. Finally, we demonstrate that Sirt6 functions as a tumor suppressor in the liver, and consequently, deletion of Sirt6 in the liver leads to not only the spontaneous development of tumors but also enhanced tumorigenesis in response to DEN treatment or under conditions of obesity.
PMID:38332150 | DOI:10.1038/s44319-024-00071-3
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
🌐 90 Days
VR Related Evidence Matrix
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study
- Occult liver disease: a multinational perspective
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Correlation between magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver biopsy to assess hepatic steatosis in obesity
- Therapeutic potential of oleanolic acid in liver diseases
- Fructose regulates the pentose phosphate pathway and induces an inflammatory and resolution phenotype in Kupffer cells
- Fructose regulates the pentose phosphate pathway and induces an inflammatory and resolution phenotype in Kupffer cells
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Suv39h1 contributes to activation of hepatic stellate cells in non-alcoholic fatty liver disease by enabling anaerobic glycolysis
- Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Emerging roles of RNA-binding proteins in fatty liver disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Adrenarche-accompanied rise of adrenal sex steroid precursors prevents NAFLD in Young Female rats by converting into active androgens and inactivating hepatic Srebf1 signaling
- Beneficial Effects of Dietary Flaxseed on Non-Alcoholic Fatty Liver Disease
- Compromised very-low density lipoprotein induced polyunsaturated triglyceride accumulation in N-nitrosodiethylamine-induced hepatic steatosis
- Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Diabetes Mellitus among Patients with Non-alcoholic Fatty Liver Disease Visiting the Outpatient Department of Internal Medicine in a Tertiary Care Centre
- Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
- Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis
- COVID-19 in Individuals with Chronic Liver Diseases
- Liver-derived extracellular vesicles improve whole-body glycaemic control via inter-organ communication
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- The levels of IL1RN is a factor influencing the onset of rheumatoid arthritis in non-alcoholic fatty liver disease
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- NcRNA Regulated Pyroptosis in Liver Diseases and Traditional Chinese Medicine Intervention: A Narrative Review
- Costunolide attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Polysaccharide from Panax japonicus C.A. Mey prevents non-alcoholic fatty liver disease development based on regulating liver metabolism and gut microbiota in mice
- Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
- Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients
- Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor)
- The GPR40 novel agonist SZZ15-11 improves non-alcoholic fatty liver disease by activating the AMPK pathway and restores metabolic homeostasis in diet-induced obese mice
- Mass spectrometry imaging-based metabolomics highlights spatial metabolic alterations in three types of liver injuries
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
- Huanglian-Hongqu herb pair improves nonalcoholic fatty liver disease via NF-κB/NLRP3 pathway in mice: network pharmacology, molecular docking and experimental validation
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Chronic exposure to ambient air pollution and the risk of non-alcoholic fatty liver disease: A cross-sectional study in Taiwan and Hong Kong
- Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review)
Evidence Blueprint
Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
🌐 365 Days
VR Related Evidence Matrix
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Menin orchestrates hepatic glucose and fatty acid uptake via deploying the cellular translocation of SIRT1 and PPARγ
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Diagnostic significance of alanine aminotransferase isoenzymes in alcoholic and non-alcoholic fatty liver cancers
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
- Bioinformatics analysis and machine learning approach applied to the identification of novel key genes involved in non-alcoholic fatty liver disease
- Liver sinusoidal endothelial transcription factors in metabolic homeostasis and disease
- Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation
- Activating transcription factor (ATF) 6 upregulates cystathionine β synthetase (CBS) expression and hydrogen sulfide (H2S) synthesis to ameliorate liver metabolic damage
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection
- How to identify at-risk NAFLD in the primary care setting
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- MBOAT7 in liver and extrahepatic diseases
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Phospholipid metabolism in the liver - Implications for phosphatidylserine in non-alcoholic fatty liver disease
- Corrected and republished from: Metabolic associated liver disease
- Fatty liver disease's renaming impacts on drug clinical trials
- Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study
- Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease
- Occult liver disease: a multinational perspective
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease
- Silencing METTL14 alleviates liver injury in non-alcoholic fatty liver disease by regulating mitochondrial homeostasis
- Thrombospondin 2 is a key determinant of fibrogenesis in non-alcoholic fatty liver disease
- Gut microbiota metabolite TMAO promoted lipid deposition and fibrosis process via KRT17 in fatty liver cells in vitro
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (Adgrf1)
- Protective effects of the succinate/SUCNR1 axis on damaged hepatocytes in NAFLD
- HMGA2 knockdown alleviates the progression of nonalcoholic fatty liver disease (NAFLD) by downregulating SNAI2 expression
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Hormone action and liver disease, a complex interplay
- TIME-RESTRICTED FEEDING COMBINED WITH RESISTANCE EXERCISE TRAINING PREVENTS OBESITY AND IMPROVES LIPID METABOLISM IN THE LIVER OF MICE FED A HIGH-FAT DIET
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Medium- and long-chain triglyceride propofol activates PI3K/AKT pathway and inhibits non-alcoholic fatty liver disease by inhibiting lipid accumulation
- Correlation between magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver biopsy to assess hepatic steatosis in obesity
- Erianin alleviated liver steatosis by enhancing Nrf2-mediated VE-cadherin expression in vascular endothelium
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Novel Effects of Prohibitin 1 Expression Level on Cholesterol and Lipid Homeostasis
- New Insights into Nutrition and Gut-Liver Axis: A Focus on Non-Alcoholic Fatty Liver Disease
- The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver disease
- Lauric acid attenuates hepato-metabolic complications and molecular alterations in high-fat diet-induced Non-alcoholic Fatty Liver Disease in rats
- Akkermansia muciniphila - a Potential Next-generation Probiotic for Non-alcoholic Fatty Liver Disease
- Galectin-12 modulates Kupffer cell polarization to alter the progression of non-alcoholic fatty liver disease
- Correction to "Ginsenoside Rc Modulates SIRT6-NRF2 Interaction to Alleviate Alcoholic Liver Disease"
- Epigenetic Regulation of Hepatic Lipid Metabolism by DNA Methylation
- Vitamin D/Vitamin D receptor pathway in nonalcoholic fatty liver disease
- Hydrogen sulfide and liver health: Insights into liver diseases
- Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD)
- Liver fat as risk factor of hepatic and cardiometabolic diseases
- Therapeutic potential of oleanolic acid in liver diseases